Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Lower LDL is Not Associated With Increased Risk of Hemorrhagic Conversion after Mechanical Thrombectomy
Cerebrovascular Disease and Interventional Neurology
P8 - Poster Session 8 (8:00 AM-9:00 AM)
4-020

To investigate the relationship between low-density lipoprotein (LDL-C) cholesterol concentration and outcomes after mechanical thrombectomy (MT) in stroke.

Recent retrospective and prospective studies have argued for a protective effect of higher LDL-C in anterior circulation ischemic stroke patients after MT, and in risk of intracranial hemorrhage in a healthy population. Our study further examines the association between LDL-C and hemorrhagic conversion (HC) in acute ischemic stroke patients who have undergone MT.

A retrospective observational study of 348 patients undergoing MT from February 2015 to July 2018 was conducted at a large comprehensive stroke center. Serum LDL-C concentrations were assessed on admission for acute ischemic stroke. Incident HC was confirmed by review of medical records for that hospitalization period. Univariate and multivariate regression models were used and outcomes were adjusted for demographics, baseline characteristics and peri-procedural and systemic complications.

A total of 336/348 patients undergoing MT had LDL-C values reported. Mean age was 71±14 (50% female, 24% African American, 42% Hispanic, 32% history of hyperlipidemia). Mean LDL-C was 85±40, median baseline modified Rankin Scale score (mRS) of 0 [IQR 0 -1], and mean admission NIHSS of 16 [IQR 11-20]. There was no statistically significant difference in odds of HC or symptomatic intracranial hemorrhage (sICH) among participants with LDL concentrations of <70 mg/dL compared with LDL-C concentrations ≥70 mg/dL, OR 0.86 [CI 0.54-1.38]. Similarly the odds of significant functional disability (mRS >3) at discharge was not significantly affected by LDL-C concentration, OR 0.81 [CI 0.51-1.27].

We did not observe a significant association between lower LDL-C and higher risk of HC, sICH or discharge mRS in acute ischemic stroke patients who have undergone mechanical thrombectomy.

Authors/Disclosures
Daniel R. Kogan, MD (University of Miami/Jackson Memorial Hospital)
PRESENTER
No disclosure on file
Vasu Saini, MD Dr. Saini has nothing to disclose.
Elizabeth Jordan No disclosure on file
Sishir Mannava, MD (UT Health) Dr. Mannava has nothing to disclose.
Nastajjia Krementz, MD (Vascular Neurology - University of Miami/Jackson Health System) Dr. Krementz has nothing to disclose.
Mario P. Zamora Dr. Zamora has nothing to disclose.
Luis Guada-Delgado, MD (University of Miami) Dr. Guada-Delgado has nothing to disclose.
Melissa Bailey, MD Dr. Bailey has nothing to disclose.
Juan Sebastian Diaz, MD (University of Miami, Dept of Neurology) No disclosure on file
Amer Malik, MD (University of Miami Miller School of Medicine) Dr. Malik has nothing to disclose.
Dileep R. Yavagal, MD, FÂé¶¹´«Ã½Ó³»­ (University of Miami Miller School of Medicine) Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vascular Dynamics. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. The institution of Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Medtronic. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus/Johnson & Johnson. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Poseydon. Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athersys. Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gravity Medical Technology. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseydon. Dr. Yavagal has stock in Poseydon. Dr. Yavagal has stock in Galaxy Therapeutics. Dr. Yavagal has stock in Stentrode. Dr. Yavagal has stock in Gravity Medical. Dr. Yavagal has stock in Gravity Medical Technology. Dr. Yavagal has stock in Athersys. Dr. Yavagal has stock in Rapid Medical . Dr. Yavagal has received intellectual property interests from a discovery or technology relating to health care. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Expert with Royal Carribean Cruise Line. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Consultant with Carnival Cruise Line.
Nicole B. Sur, MD (University of Miami) Dr. Sur has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke. The institution of Dr. Sur has received research support from Florida Stroke Registry. The institution of Dr. Sur has received research support from Miami CTSI & NIH/NINDS.